[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stable-angina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stable-angina":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,83,113,142,164,193,220,244,270,295],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100629214","prospective-lifespan-cohort-of-myocardial-infarction-100629214",false,"NCT07471763","Prospective Lifespan Cohort of Myocardial Infarction","A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System","Inclusion Criteria:\n\nAge 18 to 74 years\n\nDiagnosed with stable angina, unstable angina, or acute myocardial infarction\n\nFor acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized\n\nDiagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction\n\nWilling to participate and able to provide written informed consent\n\nAble to complete baseline assessment, biospecimen collection, and long-term follow-up\n\nExclusion Criteria:\n\nEnd-stage malignant tumor with expected survival of less than 1 year\n\nSevere hepatic or renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or Child-Pugh class C)\n\nActive autoimmune disease or long-term use of immunosuppressive agents\n\nPregnant or breastfeeding women\n\nInability to provide informed consent or severe cognitive impairment\n\nPrevious participation in another clinical study that may conflict with this project\n\nAny other condition considered by the investigators to make participation inappropriate","ALL","18 Years","74 Years",{"count":20,"type":21},6000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.\n\nThe study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.\n\nThe primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.",[25,26,27],"Acute Myocardial Infarction (AMI)","Stable Angina","Unstable Angina",[29,30,31,32,33,34,35],"prospective cohort","multi-omics","artificial intelligence","risk prediction","precision medicine","acute myocardial infarction","lifespan cohort","NOT_YET_RECRUITING","2026-03-22",{"date":39,"type":40},"2026-03-25","ACTUAL",{"date":42,"type":21},"2026-04-10",{"date":44,"type":21},"2031-04-10",{"name":46,"class":47},"Fujian Provincial Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100624681","non-surgical-periodontal-therapy-and-cardiac-biomarkers-in-stable-angina-100624681","NCT07412795","Non-Surgical Periodontal Therapy and Cardiac Biomarkers in Stable Angina","Effect of Non-Surgical Periodontal Therapy on Ischemia-Modified Albumin and Soluble ST2 in Patients With Stable Angina","Inclusion Criteria:\n\n* Willingness to participate in the study and provide written informed consent\n* Age 18 years or older\n* No periodontal treatment within the past 6 months\n* No use of local or systemic antibiotics within the past 3 months\n\nExclusion Criteria:\n\n* Unwillingness to participate in the study or to provide informed consent\n* Age under 18 years\n* Use of local or systemic antibiotics for the treatment of widespread infection\n* within the past 3 months\n* Receipt of periodontal treatment within the past 6 months\n* Pregnancy or lactation (for female participants)\n* History of acute myocardial infarction within the past 6 months",true,"65 Years",{"count":59,"type":21},60,"INTERVENTIONAL",[62],"NA","The goal of this clinical study is to learn whether gum treatment can improve heart health. Researchers will compare blood markers related to heart disease before and after routine gum treatment.\n\nThe main questions this study aims to answer are:\n\nIs gum disease a risk factor for heart disease? Can treating gum disease lower the risk of heart disease? Adults with stable angina (a type of heart disease) and adults without heart disease may take part in this study.\n\nAll participants will receive routine, non-surgical gum treatment, which is a standard dental care procedure. This includes professional cleaning to remove plaque and tartar from the teeth and practical education on tooth brushing and cleaning between the teeth. The treatment will be performed by a single researcher and completed in one visit within about one hour.\n\nParticipants will:\n\nProvide a blood sample before gum treatment Receive routine, non-surgical gum treatment Return after three months for a follow-up visit Provide a second blood sample This study does not involve experimental drugs or devices. Participation is voluntary, and there is no cost to participants. The results may help researchers better understand how gum health is related to heart health.",[26,65],"Periodontitis",[67,68,69,70,71,72,73],"Non-surgical Periodontal Treatment","Cardiovascular Disease","Cardiovascular Biomarkers","stable angina","soluble ST2","periodontitis","IMA","2026-02-13",{"date":76,"type":40},"2026-02-17",{"date":78,"type":21},"2026-02-20",{"date":80,"type":21},"2026-08-05",{"name":82,"class":47},"Ondokuz Mayıs University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":60,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100608205","oct-guided-stent-optimization-for-short-duration-dual-antiplatelet-therapy-in-stable-angina-100608205","NCT07198529","OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina","Optical Coherence Tomography for Stent Optimization and Its Impact on Short-Duration Dual Antiplatelet Therapy: A Single-Center, Prospective, Exploratory Study","COMFORT-SHORT","Inclusion Criteria:\n\n* Patients who undergo PCI using a cobalt-chromium everolimus-eluting stent (CoCr-EES)\n* Diagnosis of stable angina\n* Ability and willingness to provide written informed consent approved by the Institutional Review Board (IRB), and to comply with the study protocol and clinical follow-up schedule\n* Age ≥ 19 years\n\nExclusion Criteria:\n\n* Patients diagnosed with acute coronary syndrome (ACS), including unstable angina or acute myocardial infarction\n* Contraindications to antiplatelet therapy or OCT imaging\n* Presence of lesions with severe stenosis, heavy calcification, or marked vessel tortuosity that prevent passage of a guidewire or catheter\n* Patients with previously implanted coronary stents in the target lesion","19 Years",{"count":93,"type":21},130,[62],"This study aims to evaluate whether the use of optical coherence tomography (OCT), an advanced intravascular imaging tool, can improve stent implantation results and make it possible to shorten the duration of dual antiplatelet therapy (DAPT) in patients with stable angina who undergo percutaneous coronary intervention (PCI).\n\nPCI with drug-eluting stents is a standard treatment for patients with stable angina, and these patients are usually prescribed DAPT for 6 to 12 months to prevent stent thrombosis and other complications. However, extended use of DAPT increases the risk of bleeding, which can lead to significant medical problems, especially in patients with high bleeding risk.\n\nOCT provides detailed, high-resolution images of the coronary arteries and the implanted stents, allowing physicians to optimize stent expansion and positioning. By ensuring that the stent is well-placed and fully expanded, OCT guidance may lower the risk of complications, potentially reducing the need for prolonged DAPT.\n\nIn this prospective study, patients with stable angina who require stent implantation will be enrolled and treated with OCT-guided PCI followed by a short course of DAPT. Their outcomes will be compared with those managed using conventional strategies.\n\nThe primary goal of this trial is to determine whether OCT-guided stent optimization can safely support a short-duration DAPT strategy, thereby reducing bleeding risk without compromising protection against ischemic events such as restenosis, myocardial infarction, or stent thrombosis.",[26,97],"Coronary Artery Disease",[99,70,100,101,102],"Optical coherence tomography","dual antiplatelet therapy","stent optimization","percutaneous coronary intervention","RECRUITING","2025-12-11",{"date":106,"type":40},"2025-12-17",{"date":108,"type":40},"2025-09-30",{"date":110,"type":21},"2029-09",{"name":112,"class":47},"Korea University Guro Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":60,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":48},"100505762","perfusion-estimation-for-optimal-treatment-strategy-in-chronic-coronary-syndrome-100505762","NCT05865600","Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome","Perfusion Estimation for Optimal Revascularization and Medical Therapy in Chronic Coronary Syndrome - a Randomized Trial","PERFORM-CCS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Willing to participate and able to understand, read and sign the informed consent document before the planned procedure\n3. Known ischemic heart disease defined as one of the following\n\n   1. Previous myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting\n   2. Previous coronary computed tomography angiography or invasive coronary angiography documenting atherosclerosis.\n4. Undergoing clinically indicated \\[15O\\]H2O cardiac PET\u002FCT due to chest discomfort or dyspnea as angina equivalent\n\n   Additional inclusion criteria for randomized trial:\n5. Initial \\[15O\\]H2O cardiac PET\u002FCT with abnormal perfusion defined as all of the following\n\n   1. Hyperemic myocardial blood flow (hMBF) ≤2.3 mL\u002Fmin\u002Fg in at least two adjacent myocardial segments\n   2. Relative hMBF ≤ 65% in at least two adjacent segments as compared with the mean hMBF of the two adjacent segments with the highest mean hMBF\n   3. Tissue perfusion defect extent ≥ 5% based on indices of relative hypoperfusion\n6. Clinical indication for invasive coronary angiography decided at a multidisciplinary conference between consultants in nuclear medicine and cardiology\n\nExclusion Criteria:\n\n1. Ongoing acute coronary syndrome or acute coronary syndrome within 30 days\n2. Contraindications for adenosine\n\n   1. Severe asthma\n   2. Advanced atrioventricular block without pacemaker\n   3. Severe aortic stenosis\n3. Patients not able to breath hold (severe COPD\u002Fasthma)\n4. Pregnant women, including women who are potentially pregnant or lactating\n5. Allergy to iomeron\n6. Life expectancy of less than 2 years\n7. Severe valvular disease\n8. Reduced kidney function with an estimated glomerular filtrations rate \\\u003C40 ml\u002Fmin\n9. Inability to consent\n\n   Additional exclusion criteria for randomized trial:\n10. Unprotected left main coronary artery stenosis on coronary CT angiography\n11. Very large perfusion defect on initial \\[15O\\]H2O cardiac PET\u002FCT indicating left main coronary artery stenosis or balanced ischemia defined as tissue perfusion defect extent based on indices of absolute hMBF ≥ 20% in two or more myocardial territories supplied by coronary arteries with an Agatston calcium score ≥ 300",{"count":122,"type":21},570,[62],"We will establish a cohort of 570 symptomatic chronic coronary syndrome patients undergoing 15O-water PET and assess their symptoms through repeated questionnaires. Two hundred patients with abnormal perfusion will be randomized to immediate or delayed referral to invasive coronary angiography with concomitant optimization of guideline-directed medical therapy with repeated 15O-water PET and questionnaires at 3 and 6 months. The primary objective is to compare the potential benefit of early invasive coronary angiography (ICA) versus guideline directed medical therapy (GDMT) on symptomatic relief defined as freedom of angina after 3 months following a positive \\[15O\\]H2O cardiac PET\u002FCT in patients with symptomatic chronic coronary syndrome.",[126,127,26,97],"Chronic Coronary Syndrome","Myocardial Ischemia",[127,129,97,130,131,132],"Angina Pectoris","Coronary Angiography","Computed Tomography Angiography","Myocardial Perfusion Imaging","2025-12-03",{"date":135,"type":40},"2025-12-10",{"date":137,"type":40},"2023-05-23",{"date":139,"type":21},"2027-09-01",{"name":141,"class":47},"Gødstrup Hospital",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100458906","barts-revascularisation-registry-100458906","NCT05255705","Barts Revascularisation Registry","Barts Revascularisation Registry - To Understand the Characteristics, Time-trends and Outcomes in Patients With Coronary Artery Disease at Barts Heart Centre","Inclusion Criteria:\n\n* Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes.\n* No children will be included in this study.\n* Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Interventional Cardiology team.\n* Both male and female patients ≥16 years of age will be included\n* All patients will have had an angiogram at BHC.\n* Any patient who has undergone revascularisation.\n\nExclusion Criteria:\n\n• Patients \\\u003C16 years will not be included in this study.","16 Years",{"count":151,"type":21},20000,"Despite the year-on-year decrease, coronary artery disease (CAD) still remains one of the leading cause of mortality worldwide. With advances in technology and our understanding of cardiac disease, we can now treat CAD using minimally invasive interventional techniques. This has revolutionised treatment for and improved the lives of many patients with CAD. Although trials have assessed various therapeutic strategies in various populations, real-world evidence of intervention and medical treatment among patients with CAD is increasingly recognised as an important part of providing safety and efficacy data and improving the care we provide.\n\nThis data will add to that literature by assessing the characteristics and outcomes of patients with CAD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.",[154,26],"Myocardial Infarction","2025-07-23",{"date":157,"type":40},"2025-07-24",{"date":159,"type":40},"2021-08-06",{"date":161,"type":21},"2026-03-01",{"name":163,"class":47},"Queen Mary University of London",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":172,"conditions":173,"keywords":180,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":48},"100513945","integration-of-telemedicine-and-home-based-cardiac-rehabilitation-feasibility-efficacy-and-adherence-100513945","NCT05972070","Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence","Inclusion Criteria:\n\n1. Over the age of 18\n2. NYHA Functional Class I, II,\n3. Recent (within 60 days) status post coronary artery revascularization for atherosclerotic coronary artery disease (coronary artery bypass grafting or percutaneous coronary revascularization with stent implantation)\n4. Candidate for traditional center-based cardiac rehabilitation\n\nExclusion Criteria:\n\n1. Under the age of 18\n2. Adults lacking capacity to consent.\n3. NYHA Functional Class III, IV\n4. Acute coronary syndrome\n5. Systolic heart failure (LV EF \\\u003C40%)\n6. Status post cardiac surgery for structural heart disease or heart transplant\n7. Percutaneous coronary angioplasty\n8. Adults lacking capacity to consent.\n9. Pregnant women",{"count":171,"type":21},500,"The aim of this study is to evaluate feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine. Several components will be assessed such as quality-of-life, nutritional counseling, maximum metabolic activity (MET's), diabetic management, tobacco cessation, lipid, blood pressure, and psychosocial management. These tasks will be accomplished through concurrent conversations between patients and their therapist's utilizing telemedicine with observed exercise training.",[154,174,175,26,176,177,178,179],"Percutaneous Transluminal Coronary Angioplasty","Coronary Artery Bypass","Heart Failure","Valve Disease, Heart","Cardiac Rehabilitation","Stent",[181,182,183],"Cardiac rehabilitation","Home based cardiac rehabilitation","Telemedicine and Home-Based Cardiac Rehabilitation","2025-07-21",{"date":157,"type":40},{"date":187,"type":40},"2023-06-01",{"date":189,"type":21},"2025-12-31",{"name":191,"class":192},"ROM Technologies, INC","INDUSTRY",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":60,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100546847","multivessel-balloon-occlusion-to-investigate-obstructive-coronary-artery-disease-and-angina-100546847","NCT06400290","Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina","ORBITA-MOON","Inclusion Criteria:\n\n* Eligibility for PCI due to angina\n* Anatomical evidence of significant multi-vessel coronary stenosis defined by either:\n\n  1. ≥70% stenosis in two or more coronary arteries of ≥2.5mm visual diameter stenosis, on invasive coronary angiography (ICA)\n  2. Severe stenosis in ≥2 coronary arteries of ≥ 2.5mm visual diameter stenosis, on CTCA\n* Physiological evidence of ischaemia with a positive test corresponding to the coronary arteries to be stented, on at least one of the following:\n\n  * dobutamine stress echocardiogram\n  * cardiac MRI\n  * myocardial perfusion study\n  * invasive metrics of coronary physiology\n\nExclusion Criteria:\n\n* Recent acute coronary syndrome\n* Previous coronary artery by-pass graft surgery (CABG)\n* Significant left main stem disease\n* Chronic total occlusion in the target artery(s)\n* Moderate to severe valvular disease\n* Moderate to severe left ventricular impairment\n* Contraindication to PCI or a drug-eluting stents\n* Contraindication to antiplatelet therapy\n* Contraindication to adenosine\n* Pregnant\n* Inability to consent",{"count":59,"type":21},[62],"ORBITA-MOON is a double-blinded, placebo-controlled experimental study that aims to understand how the different coronary artery stenoses contribute to overall clinical angina in patients with multi-vessel coronary artery disease. This study will investigate the symptoms conferred by each stenosis, induced by experimental ischaemia, for 60 patients with multi-vessel coronary artery disease.",[26,204],"Multivessel Coronary Artery Disease",[206,207,208,209],"Angina","Multi-vessel coronary artery disease","Symptoms","Placebo-controlled symptom assessment","2025-06-05",{"date":212,"type":40},"2025-06-06",{"date":214,"type":40},"2024-06-13",{"date":216,"type":21},"2027-04",{"name":218,"class":47},"Imperial College London",9,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":228,"studyType":22,"phases":4,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100549597","japanese-coronary-intervention-using-drug-eluting-and-perfusion-therapy-for-left-main-disease-jdepth-lm-registry-100549597","NCT06436092","Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patient with stable coronary artery disease, non-ST-elevation myocardial infarction, or unstable angina\n3. Left main disease confirmed by coronary angiography or coronary CT angiography\n4. Clinical and anatomical eligibility for PCI as agreed by the local Heart Team\n5. Patient with consent prior to undergoing PCI\n6. Left main Medina classification (1,1,1), (1,0,1), (0,1,1), (0,0,1) confirmed by coronary angiography\n7. De novo target lesion in LMT-LAD amenable for crossover stenting with provisional side-branch approach as determined by PCI operator\n8. De novo ostial LCx lesions\n9. Lesion indicated in No. 8 with a length of less than 10 mm or a stenosis of less than 70% confirmed by coronary angiography\n\nExclusion Criteria:\n\n1. Inability to provide written informed consent\n2. Patient with a history of ST-elevation myocardial infarction within the previous 1 week\n3. Patient in a state of cardiogenic shock\n4. Patient with a history of coronary artery bypass grafting\n5. Patient with malignant tumors or other conditions with a life expectancy of less than one year\n6. Patient considered suitable for stent placement in the ostial LCx from a medical perspective\n7. Patient considered unsuitable for anti-thrombotic therapy after PCI\n8. Other patient whom the investigator deems unsuitable for the safe conduct of LM-PCI, including W-KBT",{"count":227,"type":21},280,"12 Months","JDEPTH-LM Registry is a prospective, observational, multi-center study designed for the efficacy and safety of Double-effect kissing balloon technique (W-KBT) in left main (LM) bifurcation percutaneous coronary intervention (PCI) using Perfusion balloon (PB) and Drug coated balloon (DCB) in patients with left main coronary artery disease (LMD) with left circumflex artery (LCx) ostium stenosis.",[26,231,27],"Non-ST-elevation Acute Coronary Syndrome",[233],"Ischemic heart disease","2025-03-11",{"date":236,"type":40},"2025-03-13",{"date":238,"type":40},"2024-05-27",{"date":240,"type":21},"2029-12-31",{"name":242,"class":192},"TCROSS Co., Ltd.",32,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":48},"100530404","feasibility-of-a-deep-learning-based-algorithm-for-non-invasive-assessment-of-vulnerable-coronary-plaque-100530404","NCT06186336","Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque","FOCUS DL","Inclusion Criteria:\n\n1. Patients referred for a clinically indicated CCTA and ICA with OCT imaging examinations;\n2. Diagnosis of chronic coronary syndrome, known CAD, or stable angina; AND,\n3. Patients with ACS that may undergo a CCTA and not refer directly to the Cath lab for revascularization procedures.\n\nExclusion Criteria:\n\n1. Contradictions to contrast;\n2. Contraindications for beta blocker;\n3. BMI \\>30;\n4. High heart rate ≥75 BPM;\n5. Atrial Fibrillation;\n6. Arrythmia or irregular heartbeats;\n7. Any prior coronary revascularization;\n8. Presence of pacemaker or implantable cardioverter defibrillator; OR,\n9. Patients with TAVI\u002FTAVR.",{"count":252,"type":21},200,"The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and associated vulnerability grade.",[126,97,26,255],"Acute Coronary Syndrome",[257,258,259,260],"Coronary CT Angiography","Invasive Coronary Angiography","Optical Coherence Tomography","Vulnerable Coronary Plaque","2025-01-06",{"date":263,"type":40},"2025-01-07",{"date":265,"type":21},"2025-01",{"date":267,"type":21},"2025-06",{"name":269,"class":192},"GE Healthcare",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":60,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":48},"100456965","prospective-evaluation-of-complete-revascularization-in-patients-with-multivessel-disease-excluding-chronic-total-occlusions-100456965","NCT05230446","PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions","PRESENT","Inclusion Criteria:\n\n1. Age ≥ 18 years, ≤85 years\n2. The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki\n3. Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.\n4. The patient is willing and able to cooperate with study procedures and required follow up visits\n5. The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an EC approved written informed consent, including data privacy authorization\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\> 85 years.\n2. Single coronary vessel disease.\n3. No left anterior descending lesion.\n4. Patients in cardiogenic shock.\n5. Patients with STEMI.\n6. Presence of a chronic total occlusion (CTO) defined as coronary lesion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 on initial angiography present for more than or equal to 3 months.\n7. Left main coronary artery disease\n8. Patients who cannot give informed consent or have a life expectancy of less than 12 months.\n9. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y12 inhibitors.\n10. Patients with an extreme LAD tortuosity imparing OCT catheter advancement\n11. Enrollment in another study with another investigational device or drug trial that has not reached the primary endpoint. The patient may only be enrolled once in the PRESENT study.\n12. Previous coronary artery bypass grafting (CABG).\n13. Patient requiring additional cardiac surgery within 6 months.\n14. Women of childbearing potential who do not have a negative pregnancy test result within 7 days before the procedure, women who are known to be pregnant, or who are breastfeeding.","85 Years",{"count":279,"type":21},609,[62],"This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).",[283,284,27,26,97,285,259],"Multi Vessel Coronary Artery Disease","Non-ST Elevation Myocardial Infarction","Percutaneous Coronary Intervention","2022-01-25",{"date":288,"type":40},"2022-02-09",{"date":290,"type":40},"2021-11-18",{"date":292,"type":21},"2027-11-18",{"name":294,"class":47},"Erasmus Medical Center",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":303,"targetDuration":305,"studyType":22,"phases":4,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":48},"100345729","stable-angina-management-and-treatment-100345729","NCT03781492","Stable Angina Management and Treatment","Prospective REgistry of Stable Angina manaGEment and Treatment","PRESAGE","Inclusion Criteria:\n\n* symptom based diagnosis of stable angina\n\nExclusion Criteria:\n\n* acute coronary syndrome on admission\n* ≤ 18 years old",{"count":304,"type":21},25000,"5 Years","The Prospective REgistry of Stable Angina manaGEment and Treatment (PRESAGE) is an observational study on an all-comer stable angina population hospitalised in a highly specialized cardiovascular centre with cardiac surgery facilities. The aim of the study is to assess the clinical characteristics, treatment modalities, early and long-term outcomes in this population.",[26,97],"2020-05-21",{"date":310,"type":40},"2020-05-26",{"date":312,"type":40},"2006-01-01",{"date":314,"type":21},"2026-12-31",{"name":316,"class":47},"Silesian Centre for Heart Diseases"]